FDA proposes FloLipid approval withdrawal over missing reports
The FDA has proposed withdrawing approval for Salerno Pharmaceuticals’ FloLipid, a liquid form of the cholesterol-lowering drug simvastatin, after the company repeatedly failed to file required annual reports and did not respond to the agency’s requests. The proposal covers both approved strengths and is based on reporting noncompliance, not a cited concern about the drug’s safety or effectiveness. Salerno may request an FDA hearing by Dec. 18 and, if it does, submit supporting information by Jan. 19, 2027. If approval is withdrawn, FloLipid could no longer be legally shipped across state lines, potentially leaving patients who rely on a liquid statin to find an alternative with their health care provider.







